Diakonos Oncology to Present First-in-Class DOC1021 Dendritic Cell Therapy Data at Major Cancer Conferences
Key Insights
Diakonos Oncology will present clinical data on DOC1021 (dubodencel (search)), a first-in-class patient-derived double-loaded dendritic cell therapy, at AACR and AAN conferences in April 2026.
The AACR presentation will feature updated data from the ongoing Phase 1 pancreatic cancer (search) study, while AAN will showcase first results from the expanded access glioblastoma (search) program.
DOC1021 combines tumor lysate and amplified tumor-derived mRNA to leverage a patient's full complement of tumor antigens (search) for robust immune responses against malignancy.
Diakonos Oncology Corp. (search), a clinical-stage biotechnology company, announced it will present new clinical trial data on its investigational therapy DOC1021 (dubodencel (search)) at two major medical conferences in April 2026. The American Association for Cancer Research (search) (AACR) Annual Meeting in San Diego will feature pancreatic cancer (search) data, while the American Academy of Neurology (search) (AAN) Annual Meeting in Chicago will showcase glioblastoma (search) results.
Novel Double-Loading Mechanism Shows Promise
DOC1021 represents a first-in-class, patient-derived double-loaded dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. According to Jay Hartenbach, President and COO of Diakonos Oncology, "These clinical data continue to validate DOC1021's novel mechanism, which leverages a patient's full complement of tumor antigens (search) to drive robust immune responses against malignancy."
The therapy's unique double-loading approach mimics viral infection physiologically, creating what the company describes as a synergistic and exponentially more powerful tumor killing response. This mechanism permits complete targeting of the total cancer antigen pool without requiring molecular modification or genetic engineering of the patient's immune cells.
Clinical Trial Updates Across Multiple Indications
The AACR presentation, titled "Clinical and Immunologic Assessment of DOC1021 Dendritic Cell Therapy in Resectable or Borderline Resectable Pancreatic Cancer (search)," will provide updated data from the ongoing pancreatic cancer study. The poster will be presented on Monday, April 20, from 9:00 AM–12:00 PM PT as part of the Phase I Clinical Trials in Progress session.
At AAN, researchers will present "DOC1021 Cell-based Immunotherapy in Combination with Standard Chemoradiation for Adjuvant Therapy of Glioblastoma (search): Early Results from an Expanded Access Protocol of a Phase I Trial." This marks the first report of results from the expanded access program in glioblastoma and will be presented on Wednesday, April 22, from 11:45 AM–12:45 PM CT.
Regulatory Recognition and Development Pipeline
DOC1021 has garnered significant regulatory attention, receiving FDA Fast Track designation for both the glioblastoma (search) program in October 2023 and the pancreatic cancer (search) program in May 2024. The therapy also received Orphan Drug Designation for the glioblastoma program in January 2024.
Diakonos currently operates two actively enrolling clinical trials: a Phase 1 pancreatic cancer (search) study (NCT04157127) and a Phase 2 glioblastoma (search) study (NCT06805305). The company plans to initiate a refractory melanoma (search) Phase 1/2 study (NCT07288112) early this year with support from the Cancer Prevention and Research Institute of Texas (search) (CPRIT).
Addressing High Unmet Medical Need
Hartenbach emphasized the significance of targeting these challenging malignancies, stating, "We look forward to sharing these new results and advancing this first‑in‑class therapy to improve outcomes for patients with pancreatic cancer (search) and glioblastoma (search), both of which are marked by poor prognosis and significant unmet need."
The therapy is designed for outpatient administration and broad access via community cancer centers, potentially expanding treatment options for patients with these aggressive cancers. Unlike some immunotherapies, DOC1021 does not require preconditioning chemotherapy or high-dose IL-2 for administration.